Hydroxychloroquine benefits hospitalized COVID patients
New medical study details HCQ benefits when added to a standard care protocol
The title of this new medical article is: “Hydroxychloroquine shortened hospital stay and reduced intensive care unit admissions in hospitalized COVID-19 patients.” The nearly 400 patients were elderly and had significant enough COVID symptoms to be hospitalized in 2020 in Turkey.
The study conclusions included: “Hydroxychloroquine in addition to standard of care was associated with less intensive care unit admissions, early discharge and greater C-reactive protein reduction.” The latter indicates greater reduction in inflammation.
The shorter hospital stay was quite statistically significant at 10 days with HCQ versus 12 days for just the standard care.
Intensive care admissions were also very statistically significant with 23 admissions with HCQ versus 39 admissions with standard care.
Though there was a reduction in 28 day mortality for the HCQ group, 8% versus 11.1% for standard care, it was not statistically significant.
HCQ was generally administered with a dose of 400 mg/day without loading for five days (continued for 10 days in severe cases).
In 2020, this was the headline for a study in the US: Treatment with Hydroxychloroquine Cut Death Rate Significantly in COVID-19 Patients, Henry Ford Health System Study Shows. This was stated: “In a large-scale retrospective analysis of 2,541 patients hospitalized between March 10 and May 2, 2020 across the system’s six hospitals, the study found 13% of those treated with hydroxychloroquine alone died compared to 26.4% not treated with hydroxychloroquine.”
Today, HCQ remains mostly criticized and ignored for use in hospitals despite the high death rate in US hospitals for very ill COVID patients using standard protocols.
